Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
about
Defining the intensity of conditioning regimens: working definitionsAdoptive T cell therapy for cancer in the clinicHarnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT).Immunotherapy: on the edge between experimental and clinical oncology.The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Melacine: an allogeneic melanoma tumor cell lysate vaccine.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.Pharmacological management of Ewing sarcoma family of tumours.Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapyImmunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsThe allogeneic graft-versus-cancer effect.Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility.Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens.Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning.The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation.
P2860
Q24630836-16AA9A16-20A2-4892-ACC2-759E823BB221Q24680405-863E4D30-449E-47A2-8307-8A970EA0CF29Q34089112-498D2A4E-C18A-4C1C-B74A-930109A99C64Q34135678-76EE6A96-2D1A-4256-A4C1-DDC56B4B63B9Q34172095-093A0BB6-5C9D-429F-90F9-74BB5F024D53Q34700443-5063E4D3-D034-49FD-9FD3-5FD08EAC50A1Q35022491-A1C128BC-4720-4577-BE8B-D45B3DF3292BQ35142329-95C8D77C-D280-4ABF-AF1E-34D8F1049241Q35194168-9C6D87C6-9879-4E9A-8325-7193FA6A0B69Q35690761-959C76C2-9516-44CE-8BA7-0E7BF0E2F197Q35784021-10370D83-29D2-485E-866B-08DFB04CB47BQ35849011-E8522F4B-E254-4FC7-B550-75F15E1D63F7Q36380188-2E29023F-130B-4344-ACC8-9F1EBAD03CF7Q37593125-14CE85D8-1198-42A0-930A-534F6E4CC568Q37656904-B272A58D-2F54-42F8-805B-8A8B00466674Q37716119-824AC314-EDDA-4564-8280-426A76318198Q39395107-B8B7FF2C-CB0E-4203-80C7-E26D9019E649Q40259357-F11C722C-9873-4F46-93F3-ACDBD8949CDFQ43548685-BDF96372-1D00-42DB-8007-310B8E906F36Q43622711-38B4B4BF-8A53-4D1E-8B4B-2C6143FBCA57Q43703956-19EB6BED-855E-41B3-A0A9-73238DF039B1Q43848088-1545AC36-FECA-49F7-AEF7-EC93DA6250A2Q43850963-E2FB6ACB-2C44-4457-83DD-7A85002DB066Q44351254-3FD11E2E-D4C6-4EB4-87E4-D4F767B61DC7Q44619711-2FF73D94-5D9F-4B54-A4AD-EF071352D07AQ44780698-AE93938B-2D8B-4003-B5E3-F50C643FBEE9Q47752542-8F9ABB00-4290-4992-8357-FC5E12A14859
P2860
Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Successful treatment of metast ...... r a graft-versus-tumor effect.
@ast
Successful treatment of metast ...... r a graft-versus-tumor effect.
@en
type
label
Successful treatment of metast ...... r a graft-versus-tumor effect.
@ast
Successful treatment of metast ...... r a graft-versus-tumor effect.
@en
prefLabel
Successful treatment of metast ...... r a graft-versus-tumor effect.
@ast
Successful treatment of metast ...... r a graft-versus-tumor effect.
@en
P2093
P1476
Successful treatment of metast ...... or a graft-versus-tumor effect
@en
P2093
P304
P356
10.1200/JCO.1999.17.7.2044
P407
P577
1999-07-01T00:00:00Z